Enhancing the potency of a whole-cell breast cancer vaccine in mice with an antibody-IL-2 immunocytokine that targets exposed phosphatidylserine

Vaccine

Volumn 29, Issue 29-30, 2011, Pages 4785-4793

  Huang, Xianming ^a   Ye, Dan ^a   Thorpe, Philip E ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Cancer; IL 2; Immunocytokine; Phosphatidylserine; Vaccine

Indexed keywords

2AG4 INTERLEUKIN 2 VACCINE; CANCER VACCINE; GAMMA INTERFERON; INTERLEUKIN 2; PHOSPHATIDYLSERINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CANCER; CANCER GROWTH; CANCER IMMUNIZATION; CANCER SURVIVAL; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOTOXICITY; DRUG POTENCY; FEMALE; GENETIC LINKAGE; IMMUNOGENICITY; INOCULATION; IRRADIATION; METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPLEEN CELL;

EID: 79960646478     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.04.082     Document Type: Article

References (51)

1. Degl'Innocenti E, Grioni M, Capuano G, Jachetti E, Freschi M, Bertilaccio MT, et al. Peripheral T-cell tolerance associated with prostate cancer is independent from CD4+CD25+ regulatory T cells. Cancer Res 2008;68(January (1)):292-300.
2. Marigo I, Dolcetti L, Serafini P, Zanovello P, Bronte V. Tumor-induced tolerance and immune suppression by myeloid derived suppressor cells. Immunol Rev 2008;222:162-79.
3. Ashush H, Rozenszajn LA, Blass M, Barda-Saad M, Azimov D, Radnay J, et al. Apoptosis induction of human myeloid leukemic cells by ultrasound exposure. Cancer Res 2000;60(4):1014-20.
4. Godard T, Deslandes E, Lebailly P, Vigreux C, Sichel F, Poul JM, et al. Early detection of staurosporine-induced apoptosis by comet and annexin V assays. Histochem Cell Biol 1999;112(2):155-61.
5. Fadok VA, Bratton DL, Konowal A, Freed PW, Westcott JY, Henson PM. Macrophages that have ingested apoptotic cells in vitro inhibit proinflammatory cytokine production through autocrine/paracrine mechanisms involving TGF-beta, PGE2, and PAF. J Clin Invest 1998;101(4):890-8.
6. Huynh ML, Fadok VA, Henson PM. Phosphatidylserine-dependent ingestion of apoptotic cells promotes TGF-beta1 secretion and the resolution of inflammation. J Clin Invest 2002;109(1):41-50.
7. Gaipl US, Beyer TD, Baumann I, Voll RE, Stach CM, Heyder P, et al. Exposure of anionic phospholipids serves as anti-inflammatory and immunosuppressive signal-implications for antiphospholipid syndrome and systemic lupus erythematosus. Immunobiology 2003;207(1):73-81.
8. Chen X, Doffek K, Sugg SL, Shilyansky J. Phosphatidylserine regulates the maturation of human dendritic cells. J Immunol 2004;173(5):2985-94.
9. Shi DM, Fu M, Fan PS, Li W, Chen XH, Li CX, et al. Artificial phosphatidylserine liposome mimics apoptotic cells in inhibiting maturation and immunostimulatory function of murine myeloid dendritic cells in response to 1-chloro-2,4-dinitrobenze in vitro. Arch Dermatol Res 2007;299(7):327-36.
10. He J, Yin Y, Luster TA, Watkins L, Thorpe PE. Antiphosphatidylserine antibody combined with irradiation damages tumor blood vessels and induces tumor immunity in a rat model of glioblastoma. Clin Cancer Res 2009;15(November (22)):6871-80.
11. Luster TA, He J, Huang X, Maiti SN, Schroit AJ, de Groot PG, et al. Plasma protein beta-2-glycoprotein 1 mediates interaction between the anti-tumor monoclonal antibody 3G4 and anionic phospholipids on endothelial cells. J Biol Chem 2006;281(October (40)):29863-71.
12. Ran S, Downes A, Thorpe PE. Increased exposure of anionic phospholipids on the surface of tumor blood vessels. Cancer Res 2002;62(November (21)):6132-40.
13. Ran S, He J, Huang X, Soares M, Scothorn D, Thorpe PE. Antitumor effects of a monoclonal antibody that binds anionic phospholipids on the surface of tumor blood vessels in mice. Clin Cancer Res 2005;11(February (4)):1551-62.
14. He J, Luster TA, Thorpe PE. Radiation-enhanced vascular targeting of human lung cancers in mice with a monoclonal antibody that binds anionic phospholipids. Clin Cancer Res 2007;13(September (17)):5211-8.
15. Bondanza A, Zimmermann VS, Rovere-Querini P, Turnay J, Dumitriu IE, Stach CM, et al. Inhibition of phosphatidylserine recognition heightens the immunogenicity of irradiated lymphoma cells in vivo. J Exp Med 2004;200(9):1157-65.
16. Stach CM, Turnay X, Voll RE, Kern PM, Kolowos W, Beyer TD, et al. Treatment with annexin V increases immunogenicity of apoptotic human T-cells in Balb/c mice. Cell Death Differ 2000;7(10):911-5.
17. Janke M, Peeters B, Zhao H, de Leeuw O, Moorman R, Arnold A, et al. Activation of human T cells by a tumor vaccine infected with recombinant Newcastle disease virus producing IL-2. Int J Oncol 2008;33(October (4)):823-32.
18. Gravekamp C, Leal B, Denny A, Bahar R, Lampkin S, Castro F, et al. In vivo responses to vaccination with Mage-b, GM-CSF and thioglycollate in a highly metastatic mouse breast tumor model, 4T1. Cancer Immunol Immunother 2008;57(July (7)):1067-77.
19. Russell HV, Strother D, Mei Z, Rill D, Popek E, Biagi E, et al. A phase 1/2 study of autologous neuroblastoma tumor cells genetically modified to secrete IL-2 in patients with high-risk neuroblastoma. J Immunother 2008;31(November-December (9)):812-9.
20. Grant JF, Iwasawa T, Sinn HW, Siemens DR, Griffith TS, Takacs EB, et al. Induction of protective immunity to RM-1 prostate cancer cells with ALVACIL-2/IL-12/TNF-alpha combination therapy. Int J Cancer 2006;119(December (11)):2632-41.
21. McLaughlin JP, Schlom J, Kantor JA, Greiner JW. Improved immunotherapy of a recombinant carcinoembryonic antigen vaccinia vaccine when given in combination with interleukin-2. Cancer Res 1996;56(10):2361-7.
22. Rosenberg SA, Yang JC, Schwartzentruber DJ, Hwu P, Topalian SL, Sherry RM, et al. Recombinant fowlpox viruses encoding the anchor-modified gp100 melanoma antigen can generate antitumor immune responses in patients with metastatic melanoma. Clin Cancer Res 2003;9(August (8)):2973-80.
23. Scholl S, Squiban P, Bizouarne N, Baudin M, Acres B, Mensdorff-Pouilly S, et al. Metastatic breast tumour regression following treatment by a genemodified vaccinia virus expressing MUC1 and IL-2. J Biomed Biotechnol 2003;2003(3):194-201.
24. Pantuck AJ, van Ophoven A, Gitlitz BJ, Tso CL, Acres B, Squiban P, et al. Phase I trial of antigen-specific gene therapy using a recombinant vaccinia virus encoding MUC-1 and IL-2 in MUC-1-positive patients with advanced prostate cancer. J Immunother 2004;27(May-June (3)):240-53.
25. Rouan SKE, Otterness IG, Cunningham AC, Holden HE, Rhodes CT. Reversal of colchicine-induced mitotic arrest in Chinese-Hamster cells with a colchicinespecific monoclonal-antibody. Am J Pathol 1990;137(4):779-87.
26. Ran S, Thorpe PE. Phosphatidylserine is a marker of tumor vasculature and a potential target for cancer imaging and therapy. Int J Radiat Oncol Biol Phys 2002;54(December (5)):1479-84.
27. Kwack KB, Lynch RG. A new non-radioactive method for IL-2 bioassay. Mol Cells 2000;10(5):575-8.
28. Nijhuis EHA, Poot AA, Feijen J, Vermes I. Induction of apoptosis by heat and gamma-radiation in a human lymphoid cell line; role of mitochondrial changes and caspase activation. Int J Hyperthermia 2006;22(8):687-98.
29. Pulaski BA, Terman DS, Khan S, Muller E, Ostrand-Rosenberg S. Cooperativity of Staphylococcal aureus enterotoxin B superantigen, major histocompatibility complex class II, and CD80 for immunotherapy of advanced spontaneous metastases in a clinically relevant postoperative mouse breast cancer model. Cancer Res 2000;60(May (10)):2710-5.
30. Mostbock S, Lutsiak ME, Milenic DE, Baidoo K, Schlom J, Sabzevari H. IL-2/anti-IL-2 antibody complex enhances vaccine-mediated antigen-specific CD8(+) T cell responses and increases the ratio of effector/memory CD8(+) T cells to regulatory T cells. J Immunol 2008;180(April (7)):5118-29.
31. Johnston D, Reynolds SR, Bystryn JC. Interleukin-2/liposomes potentiate immune responses to a soluble protein cancer vaccine in mice. Cancer Immunol Immunother 2006;55(April (4)):412-9.
32. Lin CT, Tsai YC, He L, Yeh CN, Chang TC, Soong YK, et al. DNA vaccines encoding IL-2 linked to HPV-16 E7 antigen generate enhanced E7-specific CTL responses and antitumor activity. Immunol Lett 2007;114(December (2)): 86-93.
33. Franki SN, Steward KK, Befting DJ, Kafi K, Yamada RE, Timmerman JM. Dendritic cells loaded with apoptotic antibody-coated tumor cells provide protective immunity against B-cell lymphoma in vivo. Blood 2008;111(February (3)):1504-11.
34. Kim PS, Armstrong TD, Song H, Wolpoe ME, Weiss V, Manning EA, et al. Antibody association with HER-2/neu-targeted vaccine enhances CD8(+) T cell responses in mice through Fc-mediated activation of DCs. J Clin Invest 2008;118(May (5)):1700-11.
35. Jinushi M, Nakazaki Y, Dougan M, Carrasco DR, Mihm M, Dranoff G. MFG-E8-mediated uptake of apoptotic cells by APCs links the pro- and antiinflammatory activities of GM-CSF. J Clin Invest 2007;117(July (7)):1902-13.
36. Park D, Hochreiter-Hufford A, Ravichandran KS. The phosphatidylserine receptor TIM-4 signaling does not mediate direct. Curr Biol 2009;19(February (4)):346-51.
37. Balasubramanian K, Schroit AJ. Characterization of phosphatidylserinedependent beta2-glycoprotein I macrophage interactions. Implications for apoptotic cell clearance by phagocytes. J Biol Chem 1998;273(October (44)):29272-7.
38. Kobayashi N, Karisola P, Pena-Cruz V, Dorfman DM, Jinushi M, Umetsu SE, et al. TIM-1 and TIM-4 glycoproteins bind phosphatidylserine and mediate uptake of apoptotic cells. Immunity 2007;27(December (6)):927-40.
39. Borisenko GG, Iverson SL, Ahlberg S, Kagan VE, Fadeel B. Milk fat globule epidermal growth factor 8 (MFG-E8) binds to oxidized phosphatidylserine: implications for macrophage clearance of apoptotic cells. Cell Death Differ 2004;11(August (8)):943-5.
40. Schuurhuis DH, Ioan-Facsinay A, Nagelkerken B, van Schip JJ, Sedlik C, Melief CJ, et al. Antigen-antibody immune complexes empower dendritic cells to efficiently prime specific CD8+ CTL responses in vivo. J Immunol 2002;168(March (5)):2240-6.
41. Rossi GR, Mautino MR, Unfer RC, Seregina TM, Vahanian N, Link CJ. Effective treatment of preexisting melanoma with whole cell vaccines expressing alpha(1,3)-galactosyl epitopes. Cancer Res 2005;65(November (22)):10555-61.
42. Abdel-Wahab Z, Dar MM, Hester D, Vervaert C, Gangavalli R, Barber J, et al. Effect of irradiation on cytokine production, MHC antigen expression, and vaccine potential of interleukin-2 and interferon-gamma gene-modified melanoma cells. Cell Immunol 1996;171(August (2)):246-54.
43. Antonia SJ, Seigne J, Diaz J, Muro-Cacho C, Extermann M, Farmelo MJ, et al. Phase I trial of a B7-1 (CD80) gene modified autologous tumor cell vaccine in combination with systemic interleukin-2 in patients with metastatic renal cell carcinoma. J Urol 2002;167(May (5)):1995-2000.
44. Babkin IV, Riazankin IA, Lebedev LR, Bulychev LE, Nesterov AE, Nosareva OV, et al. Immunogenic properties of recombinant vaccinia virus containing the human IL-2 gene. Vopr Virusol 2008;53(January-February (1)):27-31.
45. Cao X, Chen C, Zhang W, Tao Q, Yu Y, Ye T. Enhanced efficacy of combination of IL-2 gene and IL-6 gene-transfected tumor cells in the treatment of established metastatic tumors. Gene Ther 1996;3(May (5)):421-6.
46. Berntsen A, Brimnes MK, thor Straten P, Svane IM. Increase of circulating CD4+CD25 high Foxp3+ regulatory T cells in patients with metastatic renal cell carcinoma during treatment with dendritic cell vaccination and low-dose interleukin-2. J Immunother 2010;33(May (4)):425-34.
47. Grille S, Brugnini A, Nese M, Corley E, Falkenberg FW, Lens D, et al. A B-cell lymphoma vaccine using a depot formulation of interleukin-2 induces potent antitumor immunity despite increased numbers of intratumoral regulatory T cells. Cancer Immunol Immunother 2010;59(April (4)):519-27.
48. Gray A, Raff AB, Chiriva-Internati M, Chen SY, Kast WM. A paradigm shift in therapeutic vaccination of cancer patients: the need to apply therapeutic vaccination strategies in the preventive setting. Immunol Rev 2008;222:316-27.
49. Emens LA. Cancer vaccines: on the threshold of success. Expert Opin Emerg Drugs 2008;13(June (2)):295-308.
50. Tatsumi T, Takehara T, Yamaguchi S, Sasakawa A, Miyagi T, Jinushi M, et al. Injection of IL-12 gene-transduced dendritic cells into mouse liver tumor lesions activates both innate and acquired immunity. Gene Ther 2007;14(June (11)):863-71.
51. Hofbauer GF, Baur T, Bonnet MC, Tartour E, Burg G, Berinstein NL, et al. Clinical phase I intratumoral administration of two recombinant ALVAC canarypox viruses expressing human granulocyte-macrophage colony-stimulating factor or interleukin-2: the transgene determines the composition of the inflammatory infiltrate. Melanoma Res 2008;18(April (2)):104-11.